Business Information
The group's principal activities are to discover, develop and commercialize new remedies for diseases and conditions of the eye. The group develops ophthalmic drugs based on a group of natural enzymes called hyaluronidase that is used to treat diseases and conditions such as vitreous hemorrhage, diabetic retinopathy, corneal opacification and keratoconus. The major products of the group are vitrase, keratase and keraform. Vitrase is a formulation of hyaluronidase used for the treatment of vitreous hemorrhage. Keratase is a formulation of hyaluronidase used for the treatment of corneal opacification. Keraform is used for the treatment of keratoconus, a degenerative corneal disease that impairs vision. The group also develops other late-stage products, including istaloltm (timolol) for the treatment of glaucoma, xibromtm (bromfenac) for the treatment of ocular inflammation, and caprogel(R) (aminocaproic acid) for the treatment of hyphema.
|
|
Name |
Title
|
Email
|
| Richard Williams | Chmn. | Available | | Marvin Garrett | Pres. - Regulatory Affairs, Quality, Compliance | Available | | Lauren Silvernail | CFO, VP - Corporate Development | Available | | Kathleen McGinley | VP - Human Resources, Corporate Services | Available | | Kirk McMullin | VP - Operations | Available
|
|
|
Year |
Sales |
Net Income |
| 2006 | 33,007 | (38,419) | | 2005 | 10,660 | (38,480) | | 2004 | 1,897 | (40,424)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
